# US 2010/0136020 A1 · Uses of il-174 antagonists for inhibiting a th2 immune response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0136020 A1
- Document ID: US20100136020A1
- Status: Published application
- Kind: A1
- Application number: 12/614,003
- Filed: 2009-11-06
- Published: 2010-06-03
- Earliest claimed: 2000-04-18
- Assignees: Schering Corporation
- Inventors: Stephen D. Hurst; Sandra M. Zurawski; Donna M. Rennick
- Web page: https://patentgrep.com/patent/US20100136020A1

## CPC

- C07K 16/244: {Interleukins [IL]}
- A61K 38/20: Interleukins [IL]
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 1/18: for pancreatic disorders, e.g. pancreatic enzymes
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/06: Antianaemics
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/10: Antimycotics
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 33/00: Antiparasitic agents
- A61P 33/10: Anthelmintics
- A61P 33/12: Schistosomicides
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/04: Immunostimulants
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K 2039/505: {comprising antibodies}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Agonists or antagonists of cytokine designated IL-174, and various methods of their use are provided. In particular, the methods make use of facts that many activities of the IL-174 cytokine are described.

## Claims

### Claim 1

A method of:
a) directing a mammalian immune response towards a Th2 type response, said method comprising administering an IL-174 agonist to immune cells of the mammal;
b) stimulating an mammalian innate immune response, said method comprising administering an IL-174 agonist to immune cells of the mammal;
c) augmenting a mammalian inflammatory response from epithelial or fibroblast cells, said method comprising further administering an IL-174 agonist to said mammal;
d) inducing gut cell growth, said method comprising administering an IL-174 agonist to said cell;
e) promoting mammalian extra medulary hematopoiesis, said method comprising administering an IL-174 agonist to said mammal;
f) directing a mammalian immune response away from a Th2 type response, said method comprising administering an IL-174 antagonist to immune cells of the mammal;
g) preventing mammalian inflammation or granuloma formation, comprising administering an IL-174 antagonist to immune system cells; or
h) augmenting antibody response in serum and fecal material, said method comprising administering an IL-174 agonist to immune cells of the mammal.

### Claim 2 (depends on 1)

The method of claim 1:
a) directing a mammalian immune response towards a Th2 type response, said method comprising administering an M-174 agonist to immune cells of the mammal;
b) stimulating an mammalian innate immune response, said method comprising administering an IL-174 agonist to immune cells of the mammal;
c) augmenting a mammalian inflammatory response from epithelial or fibroblast cells, said method comprising further administering an IL-174 agonist to said mammal;
d) inducing gut cell growth, said method comprising administering an IL-174 agonist to said cell; or
e) promoting mammalian extra medulary hematopoiesis, said method comprising administering an IL-174 agonist to said mammal.

### Claim 3 (depends on 2)

The method of claim 2:
d) inducing gut cell growth, said method comprising administering an IL-174 agonist to said cell;
e) promoting mammalian extra medulary hematopoiesis, said method comprising administering an IL-174 agonist to said mammal.

### Claim 4 (depends on 1)

The method of claim 1:
f) directing a mammalian immune response away from a Th2 type response, said method comprising administering an IL-174 antagonist to immune cells of the mammal;
g) preventing mammalian inflammation or granuloma formation, comprising administering an IL-174 antagonist to immune system cells; or
h) augmenting antibody responses in serum and fecal material, said method comprising administering an IL-174 agonist to immune cells of the mammal.

### Claim 5 (depends on 2)

The method of claim 2 administering an agonist, wherein said administering:
a) induces cytokine production by a fibroblast, epithelial, or endothelial cell;
b) downregulates an inflammatory response which accompanies an infection;
c) stimulates growth of an epithelial cell; or
d) induces growth of gut epithelial, fibroblast, or goblet cells.

### Claim 6 (depends on 2)

The method of claim 2 administering an agonist, wherein said mammal exhibits, or has experienced conditions to stimulate:
a) an autoimmune condition;
b) an infectious disease immune response;
c) a wound healing response; or
d) a Th1 mediated condition.

### Claim 7 (depends on 6)

The method of claim 6, wherein:
a) said autoimmune condition is selected from:
i) multiple sclerosis;
ii) systemic lupus erythematosis;
iii) rheumatoid arthritis;
iv) diabetes; or
v) psoriasis;
b) said infectious response is symptomatic of:
i) an Aspergillis infection;
ii) a fungal infection, including Candidaisis, Blastomycosis, or Aspergillosis;
iii) a parasitic infection, including Schistosomiasis, fluke worm, Helminth, or Filariasis; or
iv) a viral infection, including hepatitis; or
c) said Th1 mediated condition is an inflammatory condition, including Crohn's disease, ulcerative colitis, pancreatitis, hepatitis, or eosinophilic gastritis.

### Claim 8 (depends on 7)

The method of claim 7 treating an infectious response, further comprising administering another therapeutic entity to treat said infection.

### Claim 9 (depends on 2)

A method of claim 2, stimulating an mammalian innate immune response.

### Claim 10 (depends on 4)

The method of claim 4 administering an antagonist, wherein said antagonist is a monoclonal antibody against IL-174.

### Claim 11 (depends on 4)

The method of claim 4 administering an antagonist, wherein:
a) said administering blocks eosinophil attraction, tissue remodeling, or fibrosis; or
b) said mammal exhibits, or has experienced conditions to stimulate:
i) an allergic condition;
ii) an inflammatory condition; or
iii) a Th2 mediated condition.

### Claim 12 (depends on 11)

The method of claim 11, wherein:
a) said eosinophils are attracted to the lung, liver or intestine
b) said fibrosis is pancreatic duct or peribiliary fibrosis;
c) said antagonist suppresses production of IL-4, IL-5, and/or IL-13;
d) said antagonist decreases eotaxin, CCR4, and/or CCR4 expression in BAL;
e) symptoms of said allergic condition are in the lung;
f) said allergic condition is a systemic anaphylactic response, skin hypersensitivity response, or a food allergy; or
g) said inflammatory or Th2 mediated condition is a dermatitis or asthmatic inflammation.

### Claim 13 (depends on 11)

The method of claim 11, wherein said mammal exhibits, or has experienced conditions to stimulate:
a) an allergic condition;
b) an inflammatory condition; or
c) a Th2 mediated condition.

### Claim 14

A composition comprising:
a) an IL-174 agonist and:
i) an antimicrobial, including an antibiotic, antiviral, or antifungal compound; or
ii) a chemotherapy agent; or
b) an IL-174 antagonist and:
i) an allergy medicament;
ii) an asthma medicament;
iii) a dermatitis medicament;
iv) a fibrosis medicament; or
v) an eosinophilic gastritis medicament.
